REGN vs VRTX Stock Comparison: AI Score, Valuation, Performance and Upside
Both REGN and VRTX are elite large-cap biotechs with dominant, high-profit franchise drugs and strong internal R&D capabilities. Regeneron's Dupixent offers broader commercial reach across common inflammatory diseases, while Vertex's CF monopoly generates exceptional profit margins from a specialized rare disease franchise — both are compounding profitable biotech investments.
REGN vs VRTX compares two of biotech's premier large-cap franchises: Regeneron's Dupixent-led inflammatory disease platform versus Vertex's near-monopoly cystic fibrosis franchise.
VRTX holds the edge across 3 of 5 key metrics in this comparison. VRTX has delivered stronger 1-year price return (+31.32% vs +31.09%), though REGN has the better forward P/E setup (13.10x vs 24.63x for VRTX). On fundamentals, REGN is growing revenue faster (16.70%), while VRTX maintains the higher operating margin (38.05%) — a classic growth-versus-profitability split. Analyst consensus implies similar upside for both: +5.82% for REGN and +3.96% for VRTX.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to a large-cap biotech with a commercially proven, multi-indication blockbuster in Dupixent
- Value Regeneron's track record of internal drug discovery and commercialization across multiple products
- Believe Dupixent's continued indication expansion can sustain its revenue growth trajectory
- Want exposure to a large-cap biotech with exceptional profitability from a near-monopoly CF franchise
- Believe suzetrigine non-opioid pain represents a significant new commercial opportunity
- Value Vertex's strong free cash flow generation enabling pipeline investment without dilution
| Metric | REGN | VRTX |
|---|---|---|
| AI scorei | 43.7 | 53.5 |
| AI ranki | #860 | #334 |
| Latest closei | $784.85 | $508.34 |
| 1M returni | -6.66% | -7.92% |
| 6M returni | +6.43% | +10.98% |
| 1Y returni | +31.09% | +31.32% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | REGN | VRTX |
|---|---|---|
| 1Y ago | $13.11K (+31.1%) started 2025-09-18 | $13.13K (+31.3%) started 2025-09-18 |
| 5Y ago | $12.3K (+23.0%) started 2021-09-20 | $27.38K (+173.8%) started 2021-09-20 |
| 10Y ago | $19.56K (+95.6%) started 2016-09-19 | $55.7K (+457.0%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | REGN | VRTX |
|---|---|---|
| Market capi | $81.77B | $137.3B |
| Trailing P/Ei | 19.65 | 31.55 |
| Forward P/Ei | 13.10 | 24.63 |
| Price/Salesi | 3.78 | 10.42 |
| EV/Revenuei | 4.76 | 10.44 |
| Analyst targeti | $840.43 | $563.12 |
| Target upsidei | +5.82% | +3.96% |
| Metric | REGN | VRTX |
|---|---|---|
| Revenue growthi | 16.70% | 12.50% |
| Earnings growthi | -4.50% | 8.00% |
| EPS growthi | -4.50% | +8.00% |
| FCF margini | +19.73% | +20.88% |
| Operating margini | 33.11% | 38.05% |
| Profit margini | 27.87% | 35.00% |
| ROIC proxyi | 14.04% | 23.54% |
| Return on equityi | 14.04% | 23.54% |
| Dividend yieldi | 0.47% | N/A |
| Payout ratioi | 9.01% | 0.00% |
| Dividend growth streaki | No increase yet | N/A |
| Betai | 0.19 | 0.30 |
| Debt/equityi | 8.54 | 9.77 |
| Current ratioi | 3.33 | 3.19 |
| Quick ratioi | 2.63 | 2.54 |
Over the past year, REGN and VRTX have moved moderately in the same direction (correlation of 0.40), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | REGN | VRTX |
|---|---|---|---|
| 1Y | Growthi | +31.09% | +31.32% |
| CAGRi | +31.11% | +31.34% | |
| Volatilityi | 33.54% | 28.72% | |
| Sharpe ratioi | 0.84 | 0.94 | |
| Sortino ratioi | 1.31 | 1.56 | |
| Max drawdowni | 26.05% | 15.21% | |
| Current drawdowni | 7.88% | 8.89% | |
| Avg drawdowni | 8.23% | 5.53% | |
| Ulcer Indexi | 11.06% | 7.25% | |
| Max daily dropi | 9.82% | 4.56% | |
| Max wkly dropi | 12.87% | 9.32% | |
| 5Y | Growthi | +22.80% | +173.79% |
| CAGRi | +4.20% | +22.34% | |
| Volatilityi | 31.12% | 28.96% | |
| Sharpe ratioi | 0.14 | 0.69 | |
| Sortino ratioi | 0.20 | 0.97 | |
| Max drawdowni | 59.69% | 29.07% | |
| Current drawdowni | 34.51% | 8.89% | |
| Avg drawdowni | 20.20% | 7.22% | |
| Ulcer Indexi | 27.95% | 9.56% | |
| Max daily dropi | 19.01% | 20.60% | |
| Max wkly dropi | 20.21% | 20.71% | |
| 10Y | Growthi | +95.37% | +457.02% |
| CAGRi | +6.93% | +18.74% | |
| Volatilityi | 32.13% | 32.67% | |
| Sharpe ratioi | 0.23 | 0.55 | |
| Sortino ratioi | 0.34 | 0.82 | |
| Max drawdowni | 59.69% | 41.60% | |
| Current drawdowni | 34.51% | 8.89% | |
| Avg drawdowni | 21.33% | 10.93% | |
| Ulcer Indexi | 26.89% | 14.67% | |
| Max daily dropi | 19.01% | 20.70% | |
| Max wkly dropi | 20.21% | 22.29% |
| Category | REGN | VRTX |
|---|---|---|
| Company | Regeneron Pharmaceuticals, Inc. | Vertex Pharmaceuticals Incorporated |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Core business | Regeneron is a large-cap biotechnology company known for its blockbuster drugs Dupixent (atopic dermatitis, asthma) and Eylea (wet AMD), with a broad pipeline including antibody-based therapies, bispecific antibodies, and gene editing approaches. | Vertex is a large-cap biotechnology company that has established a near-monopoly in cystic fibrosis (CF) treatments with its Trikafta/Kaftrio franchise, generating substantial profits while expanding into pain, kidney disease, and cell therapy through CRISPR-based approaches. |
| Investor focus | Investors track Dupixent's continued revenue growth across its expanding indications, Eylea's defense against biosimilar competition, and the advancement of next-generation products in the pipeline. | Investors track Vertex's CF franchise durability and patient uptake, progress of pipeline programs in non-opioid pain (suzetrigine), kidney disease (inaxaplin), and its CRISPR-based gene therapy collaboration with CRISPR Therapeutics. |
- Dupixent is one of the best-selling drugs globally with continued growth driven by new indications in atopic dermatitis, asthma, COPD, and beyond
- Strong internal drug discovery capabilities with a track record of bringing multiple successful drugs to market
- Eylea (aflibercept) remains a leading treatment for retinal diseases despite biosimilar entry
- Near-monopoly position in cystic fibrosis treatment with Trikafta generating billions in highly profitable revenue
- Strong free cash flow from CF franchise funds pipeline expansion without capital market dependency
- Non-opioid pain drug (suzetrigine) represents a potential major new franchise outside CF
- Eylea is facing increasing biosimilar competition that will pressure its revenue over time
- Dupixent will eventually face biosimilar competition as its patents approach expiration
- Continued pipeline investment is critical to sustaining growth as current franchise products mature
- CF franchise is highly concentrated in a rare disease with a finite patient population that is gradually being addressed
- Suzetrigine pain franchise faces a long commercial build and competition from existing pain management approaches
- Gene therapy programs remain high-risk and early-stage despite significant investment
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.